Posted by Michael Wonder on 30 Nov 2018
Decision to fund ceftriaxone in the community for suspected meningococcal disease
30 November 2018 - PHARMAC has widened funded access to ceftriaxone to enable its use for the treatment of suspected meningococcal disease in the community. This change will be activated from 1 December 2018.
Following clinical advice received from the Ministry of Health and the Anti-Infective Subcommittee of PTAC, the following changes will be made to the listing of ceftriaxone injection in Section B of the Pharmaceutical Schedule:
- the criteria for subsidy by endorsement will include the treatment of suspected meningococcal disease in any patient;
- the number of vials of ceftriaxone available via a Practitioner’s Supply Order will increase from 5 vials to 10 vials.
This decision requires out of cycle changes to the Pharmaceutical Schedule.
